Samnir

Cefdinir

Susceptible infections eg, URTI (acute bacterial otitis media, acute maxillary sinusitis, acute recurrent or chronic tonsillitis/pharyngitis); lower resp tract infections (community-acquired pneumonia, acute exacerbation of chronic bronchitis, secondary bacterial infections of acute bronchitis); uncomplicated skin & skin structure infections.

Cap Adult & adolescent ≥13 yr 100 mg tid (every 8 hr). Acute maxillary sinusitis 300 mg bid (every 12 hr) or 600 mg once daily for 10 days. Pharyngitis & tonsillitis, & acute exacerbations of chronic bronchitis 300 mg bid (every 12 hr) for 5-10 days or 600 mg once daily for 10 days. Community-acquired pneumonia 300 mg bid (every 12 hr) for 10 days. Susp Childn & infant 6 mth to 12 yr Max: 14 mg/kg daily. Acute bacterial otitis media, pharyngitis & tonsillitis 7 mg/kg every 12 hr for 5-10 days or 14 mg/kg every 24 hr for 10 days. Acute maxillary sinusitis 7 mg/kg every 12 hr or 14 mg/kg every 24 hr for 10 days. Uncomplicated skin & skin structure infections 7 mg/kg every 12 hr for 10 days. Adult w/ renal impairment (CrCl <30 mL/min/1.73 m²) 300 mg once daily. Childn w/ renal impairment (CrCl <30 mL/min/1.73 m²) 7 mg/kg once daily. Patient on hemodialysis Initially 300 mg or 7 mg/kg on each hemodialysis session. Subsequently, 300 mg or 7 mg/kg every other day. Additional dose of 300 mg or 7 mg/kg should be given 48 hr after the last dialysis session if the interval between dialysis session exceeds 48 hr.

May be taken with or without food.

Hypersensitivity to cefdinir, other cephalosporins or related antibiotics.

Severe to fatal allergic reaction in patients w/ hypersensitivity to penicillins. Stop treatment if any signs & symptoms eg, fever, skin rash, blisters, detachment of skin & epithelial lining in oral cavity, throat, nose, genital organ & conjunctivitis occur. Possible overgrowth of resistant organisms. Mild cases of pseudomembranous colitis. Patients w/ history of hypersensitivity to penicillins, other cephalosporins & patients w/ personal or familial predisposition to allergic reactions eg, asthma, rash or urticaria; GI disease, particularly colitis. Manage w/ fluids, electrolytes, protein supplementation & treatment w/ antibacterial drug clinically effective against Clostridium difficile. Renal impairment. Pregnancy & lactation. Not to be used in neonates & infants <6 mth.

Diarrhea, rash, vomiting, skin candida, abdominal pain, leucopenia, vulvovag candidiasis, vag infection, dyspepsia, hyperkinesia, increased AST, maculopapular rash, nausea. Increased/decreased lymphocytes & polymorphonuclear neutrophils, increased alkaline phosphatase, eosinophils, LDH & platelets, decreased bicarbonate & granulocytes, proteinuria, SJS, conjunctivitis, TEN, stomatitis, erythema multiforme, fulminant hepatitis, cholestasis, acute hepatitis, melaena, hepatic failure, jaundice, anaphylactic shock, face & laryngeal edema, exfoliative dermatitis, suffocation feeling, acute enterocolitis, bloody stool, pseudomembranous colitis, pancytopenia, drug-induced pneumonia, hemolytic anemia, thrombocytopenia, fever, chest pain, resp failure, asthma, acute renal failure, haemorrhagic diathesis, coagulopathy, peptic ulcer, loss of consciousness, cardiac failure, HTN, MI, involuntary movement, rhabdomyolysis. False +ve reaction in urine for ketones & glucose; in direct Coomb's test.

Reduced absorption w/ antacid; therapeutic Fe supplement. Increased plasma level & prolonged elimination t_½ w/ probenecid.

Cephalosporins

J01DD15 - cefdinir ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.

D